Sarepta Therapeutics Inc
SRPT
NASDAQ
Biotechnology
$18.10
USD
-0.32 (-1.74%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.94B
Volume 1.6M
Revenue
$1.97B
TTM
-20.4%
YoY
Gross Margin
59%
TTM
-25.5%
YoY
Net Income
$-136.72M
TTM
-135.9%
YoY
Operating Cash Flow
$111.01M
TTM
+136.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 611.1 | 399.4 | 442.9 | 730.8 | 401.3 |
YoY Growth | +68.4% | -14.5% | -32.7% | -1.9% | -34.3% |
Cost of Revenue | 152.6 | 150.8 | 398.7 | 108.8 | 149.4 |
Gross Profit | 458.5 | 248.6 | 44.2 | 622.0 | 251.9 |
Selling, General & Administrative | 137.9 | 91.9 | 128.3 | 109.0 | 107.6 |
Other Operating Expenses | 0.0 | 40.5 | 1.5 | 0.0 | 39.0 |
Total Operating Expenses | 343.0 | 352.0 | 455.8 | 263.6 | 238.6 |
Operating Income | 115.6 | -103.4 | -411.6 | 358.4 | 13.3 |
EBITDA | 126.4 | -44.4 | -404.8 | 369.0 | 62.7 |
Other Income / Expense | 38.1 | -90.7 | 133.3 | -15.3 | -15.0 |
Total Other Income / Expense | 38.1 | -90.7 | 133.3 | -15.3 | -15.0 |
Income Before Income Taxes | 153.6 | -194.0 | -278.3 | 343.2 | -1.7 |
Income Taxes | -43.3 | -14.1 | 4.6 | 12.2 | 3.1 |
Net Income | 196.9 | -179.9 | -282.8 | 331.0 | -4.9 |
Consolidated Net Income / Loss | 196.9 | -179.9 | -282.8 | 331.0 | -4.9 |
Net Income Attributable to Common Shareholders | 196.9 | -179.9 | -282.8 | 331.0 | -4.9 |
Basic EPS | $2.01 | -$1.80 | -$2.70 | $3.15 | -$0.05 |
Diluted EPS | $1.89 | -$1.80 | -$2.94 | $2.88 | -$0.05 |
Basic Shares Outstanding | 98.0M | 100.2M | 104.9M | 105.0M | 105.4M |
Diluted Shares Outstanding | 106.6M | 100.2M | 96.3M | 121.9M | 105.4M |